Chemical Identity and Pharmaceutical Significance
Chemical suppliers recognize stachydrine hydrochloride (CAS 4136-37-2, C?H??ClNO?, MW 179.64) as a key alkaloid from Leonurus japonicus. This quaternary ammonium compound exhibits water solubility and reactivity suitable for diverse dosage forms. Chemical suppliers position this white crystalline powder as a high-purity pharmaceutical intermediate, with commercial grades reaching 98-99.92% purity for research and drug development applications.
Cardiovascular Protective Mechanisms
Chemical suppliers support research demonstrating stachydrine hydrochloride’s cardioprotective activity. Studies show it reduces pressure overload-induced cardiac insufficiency by inhibiting NOX2 activity and suppressing oxidative stress. The compound downregulates gp91phox expression, prevents p67phox and p47phox membrane translocation, and restores myocardial function. Chemical suppliers providing high-purity material enable these mechanistic investigations critical for cardiovascular drug development.
Uterotonic and Gynecological Applications
Chemical suppliers serve pharmaceutical manufacturers developing stachydrine hydrochloride-based uterotonic drugs. The compound induces rhythmic uterine contractions, supporting postpartum recovery and hemorrhage reduction. Chinese pharmacopoeia standards require specific content in formulations like fresh Leonurus capsules (≥8.4 mg per capsule). Chemical suppliers must deliver consistent quality to meet these regulatory requirements for maternal healthcare products.
Cerebrovascular Protection and Neuropharmacology
Research confirms stachydrine hydrochloride’s cerebroprotective effects. Animal studies demonstrate significant reduction in cerebral infarction volume and brain water content following treatment. The compound activates Wnt/β-catenin signaling, increasing β-catenin and cyclin D1 protein levels. Chemical suppliers providing this compound facilitate development of ischemic stroke therapies, addressing critical unmet medical needs in neuropharmacology.
Extraction and Purification Technologies
Chemical suppliers employ advanced purification methods for pharmaceutical-grade stachydrine hydrochloride. Processes include water extraction, ethanol precipitation, macroporous resin chromatography (D101), and recrystallization from butanol/acetonitrile mixtures. Optimized protocols achieve 81.9% yield and 99.66% HPLC purity. Chemical suppliers continuously refine these techniques to meet increasing demand for high-purity material in drug manufacturing.
Crystal Form and Stability Engineering
Chemical suppliers address stachydrine hydrochloride’s hygroscopic nature through crystal form innovation. A patented crystalline form with characteristic X-ray powder diffraction peaks at 2θ values (10.08°, 12.75°, 13.32°, 14.42°, 15.89°) demonstrates superior stability against light degradation and moisture absorption. Chemical suppliers adopting this crystal form technology significantly improve drug safety and shelf-life for pharmaceutical formulations.
Market Landscape and Supply Chain
The global chemical suppliers network for stachydrine hydrochloride includes manufacturers across China, with major players in Hubei, Shaanxi, and Sichuan provinces. Commercial pricing ranges from $1-$79 per unit depending on purity and quantity. Chemical suppliers compete on quality consistency, regulatory compliance, and technical support, serving pharmaceutical companies, research institutions, and contract manufacturing organizations worldwide.
Future Directions in Pharmaceutical Development
Chemical suppliers anticipate expanding stachydrine hydrochloride applications in cardiovascular therapeutics, neuroprotection, and anti-inflammatory drugs. Ongoing research explores NF-κB pathway inhibition and anti-cancer mechanisms. As clinical evidence accumulates, chemical suppliers will scale production capacities and develop specialized formulations. Their role in bridging natural product chemistry and pharmaceutical innovation ensures stachydrine hydrochloride’s continued therapeutic advancement.
Comments